Clinical Trial

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 20, 2025 (before its estimated May 13, 2026 completion). Its status may not reflect the trial's current state.
Summary
In this phase Ib/II study, participants with metastatic castration-resistant prostate cancer (mCRPC) who failed prior novel hormone therapy will be treated with XNW5004 in combination with enzalutamide.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-20.
Status change: Enrolling by Invitation → Recruiting 2025-04-17
Trial Details
NCT Number NCT06702995
Lead Sponsor Evopoint Biosciences Inc.
Conditions Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Enrollment 307 participants
Start Date 2023-04-19
Primary Completion 2026-05-13 (estimated)
Study Completion 2026-07-19 (estimated)
Updated on ClinicalTrials.gov 2025-04-20